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Abstract
Background: Although the connection between ascending infection and preterm birth is undisputed, research
focused on finding effective treatments has been disappointing. However evidence that eradication of Candida in
pregnancy may reduce the risk of preterm birth is emerging. We conducted a pilot study to assess the feasibility of
conducting a large randomized controlled trial to determine whether treatment of asymptomatic candidiasis in
early pregnancy reduces the incidence of preterm birth.
Methods: We used a prospective, randomized, open-label, blinded-endpoint (PROBE) study design. Pregnant
women presenting at <20 weeks gestation with singleton pregnancies self-collected a vaginal swab. Those who
were asymptomatic and culture positive for Candida were randomized to 6-days of clotrimazole vaginal pessaries
(100mg) or usual care (screening result is not revealed, no treatment). The primary outcomes were the rate of
asymptomatic vaginal candidiasis, participation and follow-up. The proposed primary trial outcome of spontaneous
preterm birth <37 weeks gestation was also assessed.
Results: Of 779 women approached, 500 (64%) participated in candidiasis screening, and 98 (19.6%) had
asymptomatic vaginal candidiasis and were randomized to clotrimazole or usual care. Women were not
inconvenienced by participation in the study, laboratory testing and medication dispensing were problem-free, and
the follow-up rate was 99%. There was a tendency towards a reduction in spontaneous preterm birth among
women with asymptomatic candidiasis who were treated with clotrimazole RR = 0.33, 95%CI 0.04-3.03.
Conclusions: A large, adequately powered, randomized trial of clotrimazole to prevent preterm birth in women
with asymptomatic candidiasis is both feasible and warranted.
Trial registration: Australia and New Zealand Clinical Trials Register (ANZCTR): ACTRN12609001052224
Background
Prevention of spontaneous preterm birth remains one of
the most important challenges in modern maternity
care. Whilst an association between ascending infection
and preterm birth is undisputed, research focussed on
finding effective preventive treatments has been disap-
pointing [1]. To date, most treatment trials (e.g. for bac-
terial vaginosis, Ureaplasma urealyticum, Chlamydia
trachomatis, trichomoniasis) have found little effect on
the rate of preterm birth [2]. In contrast, in a rando-
mized controlled trial of early antenatal screening
(15-19 weeks) and treatment for asymptomatic bacterial
vaginosis, candidiasis and/or trichomoniasis in early
pregnancy, Kiss and colleagues reported a 46% reduction
in the spontaneous preterm birth rate [3]. Post-hoc sub-
g r o u pa n a l y s e so ft h i st r i a ls u g g e s tt h eb e n e f i tw a s
primarily among those women who were treated for
asymptomatic candidiasis.
The results of observational studies of the association
between candidiasis and preterm birth have been mixed.
Two cohort studies conducted in high-risk obstetric
populations in the United States in the 1980 s found no
significant association between preterm birth and mod-
erate to heavy growth of Candida albicans or other
Candida species at 22-30 weeks gestation [4,5], In
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term birth in population-based data from Hungary
found that vaginal clotrimazole treatment of candidiasis
during pregnancy was associated with a significantly
higher mean gestational age, resulting in a 34-64%
reduction in the prevalence of preterm birth [6-8]. A
similar reduction in preterm birth (49%) was observed
in retrospective study of Latina women in New York
who were treated with intravaginal azoles for Candida
vaginitis [9]
Pregnant women have a two-fold increase in the pre-
valence of vaginal colonization by Candida species
compared with non-pregnant women [10]. This asso-
ciation is influenced by increased levels of circulating
oestrogens and deposition of glycogen and other sub-
strates in the vagina during pregnancy [10]. Trials of
treatment of candidiasis in pregnancy have been lim-
ited to women with symptomatic candidiasis (thrush)
and the outcome limited to successful eradication of
Candida colonization and amelioration of symptoms,
not pregnancy outcomes [11]. Women with sympto-
matic candidiasis cannot ethically be randomized to a
‘no treatment’ trial arm, whereas currently, asympto-
matic Candida colonization is not considered to
require treatment. Consequently, we undertook a pilot
study to determine the feasibility of conducting a large
randomized controlled trial to answer the clinical
question ‘In pregnant women with asymptomatic can-
didiasis does treatment with clotrimazole reduce the
incidence of preterm birth?’ In addition to assessing
procedural feasibility, the aim of the pilot study was to
determine the rate of asymptomatic vaginal candidiasis
<20 weeks gestation and at 24-28 weeks gestation in
an unselected maternity population.
Methods
This open-label pilot study was conducted in a single
Australian tertiary obstetric hospital with recruitment
between May 2008 and December 2009. Eligible women
included those with a singleton pregnancy of 12 to 19
weeks gestation, aged 18 years or over, no symptoms of
vaginal candidiasis at the time of recruitment and no
known sensitivity to clotrimazole. Women were
recruited by research midwives during a routine antena-
tal clinic visit. All women provided written informed
consent prior to entry into the study. Participants were
advised at study entry to seek medical attention from
their local doctor or other antenatal care provider if
symptoms of thrush developed at any stage in their
pregnancy.
Baseline data (age, gravidity, parity and previous pre-
term birth) were collected at the time of obtaining
informed consent and women were instructed on the
self-collection of a vaginal swab for isolation of Candida
species. Such self-collection is commonly used for
screening in pregnancy [12]. All women with Candida
isolated on the initial swab and a random sample of
women without candidiasis were asked to provide a sec-
ond vaginal swab at 24-28 weeks.
All vaginal swabs were received within 24 hours of
collection and inoculated onto full plates of chromo-
genic agar (CHROMagar™Candida, CHROMagar, Paris,
France) to isolate, provisionally speciate and semi-quan-
titatively enumerate Candida species (scant, moderate,
or heavy). Cultures were incubated for 72 hours at 35
degrees Celsius in 5% CO2. Identification to species
level was based on colony morphology and color.
Pilot randomized controlled trial
Women with asymptomatic Candida colonization were
randomized (central telephone randomisation) to receive
either clotrimazole (Canestan
®) 100 mg vaginal pessaries
for 6 nights) or usual care (screening result not revealed,
no treatment, routine antenatal care). The clotrimazole
could be collected from the hospital, or where this was
not feasible it was mailed.
This was a prospective, randomized, open-label,
blinded-endpoint (PROBE) trial [13]. Although women
and their care providers were not informed of swab
results, those randomized to the treatment group were
aware of the result because of their allocation to receive
medication. The primary trial outcome was birth <37
weeks gestation following spontaneous onset of labor or
following preterm prelabor rupture of membranes
(PPROM). Gestational age was based on a 1
st trimester
ultrasound scan. Other outcomes (pregnancy complica-
tions, elective preterm delivery, mode of delivery and
infant outcomes) were abstracted from the medical
records.
Sample size and statistical analysis
A sample size of 500 women was selected to determine
the rate of asymptomatic candidiasis, pilot test the study
procedures, and help inform the recruitment numbers
and sample size for a definitive trial. The overall coloni-
zation rate and its 95% confidence interval (CI) were
determined and descriptive analyses of women with and
without asymptomatic candidiasis were undertaken. Dif-
ferences between the two groups were assessed by chi-
square tests with the P value set at 0.05.
All trial analyses were by intention to treat, including
one woman without candidiasis who was inadvertently
randomized to the usual care group. The relative risk
(RR) and 95% confidence interval (95%CI) of preterm
birth and other outcomes were calculated for women
assigned to clotrimazole compared to usual care. The
study was approved by the Northern Sydney Central
Coast Health Service Ethics Committee.
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Screening for asymptomatic candidiasis
Of 779 women approached, 500 (64%) agreed to partici-
pate in the study. For one woman, the swab result was
not obtained. Of the remaining 499 women, 98 (19.6%,
95%CI 16.2-23.1%) women had asymptomatic candidia-
sis. Women with asymptomatic candidiasis were similar
to those women without candidiasis with respect to age,
gravidity, parity and history of previous preterm birth
(Table 1). The overall preterm birth rate among those
women without Candida colonization was 3.7%, includ-
ing 3.0% with spontaneous preterm birth or PPROM. Of
28 women without candidiasis at enrolment who had a
2
nd vaginal swab, one had scant Candida albicans at 24-
28 weeks.
Of the women with candidiasis, 72 (73%) were colo-
nized with Candida albicans,1 4( 1 4 . 3 % )Candida glab-
rata,5( 5 . 1 % )Candida parapsilosis, 3 (3.1%) each of
Candida krusei and Candida tropicalis and 1 (1%) Tri-
chosporon inkin species. Semi-quantitative enumeration
was reported for 94 specimens; 48 (51%) scant, 34 (36%)
moderate and 12 (13%) heavy colonisation.
Pilot randomized controlled trial
Fifty women with asymptomatic candidiasis were rando-
mized to clotrimazole and 49 to usual care. The baseline
characteristics of each group varied consistent with the
small number randomized (Table 2). One woman in the
usual care group moved interstate and was lost to fol-
low-up. Trial outcomes are reported in Table 3. Five
women delivered preterm, 2 (4.0%) in the clotrimazole
group and 3 (6.3%) in the usual care group. Except for
one woman in the clotrimazole group who was delivered
electively for preeclampsia, all followed PPROM and/or
spontaneous preterm labour (RR = 0.33 95%CI 0.04-
3.03). There were no infants with an Apgar score <7 at
5 minutes and no perinatal deaths.
Ninety five (96%) women with asymptomatic candidia-
sis had a 2
nd vaginal swab at 24-28 weeks. The mean
duration between first and second vaginal swabs was 10
weeks in both arms of the trial. The colonization rates
at 24-28 weeks were: 49% in those treated with clotri-
mazole, with the rate of moderate-heavy colonization
55% at enrolment and 42% at 24-28 weeks (P = 0.3);
76% in those in the usual care group with moderate-
heavy colonization rates of 42% and 40% respectively.
For women with candidiasis both at enrolment and at
24-28 weeks the Candida species remained the same
except for one woman in the no treatment group where
the species changed from C. glabrata to C. kefyr.
Discussion
We have demonstrated the feasibility of performing a
randomized controlled trial of clotrimazole for pregnant
women with asymptomatic candidiasis. The participa-
tion rate (64%) was acceptable, women were not incon-
venienced by participation in the study, laboratory
testing and medication dispensing were problem free,
and the follow-up rate was 99%. Although there were
no statistically significant differences in outcomes
between treatment groups, the findings were in the
direction of a treatment effect.
We chose a PROBE design to overcome some specific
disadvantages associated with a double-blind, placebo-
controlled trial for answering our clinical question
[13,14]. First, for our hypothesis, a placebo arm would
not represent current clinical practice (no screening and
no treatment). Second we were concerned that knowl-
edge of Candida colonization might change participants
behavior such that they would seek active therapy
Table 1 Characteristics of asymptomatic women by
Candida colonization
Maternal baseline
characteristics
Colonized
N=9 8
n (%)
Not
colonized
N = 400
n (%)
P-
value
Age (years)
18-34 64 (65) 234 (59) 0.22
≥ 35 34 (35) 166 (41)
Gravidity/parity
Nulligravida 25 (26) 125 (31) 0.27
Nullipara 19 (18) 53 (13)
Multipara 54 (55) 222 (56)
Previous preterm birth 4 (4) 17 (4) 0.94
Gravidity = number of pregnancies.
Parity = number of births ≥20 weeks or ≥400 grams.
Table 2 Baseline characteristics of women randomized to
clotrimazole and usual care
Maternal baseline characteristics Clotrimazole
N=5 0
n (%)
Usual care
N=4 9
n (%)
Age (years)
18-34 28 (56) 36 (73)
≥ 35 22 (44) 13 (27)
Gravidity/parity
Nulligravida 11 (22) 14 (29)
Nullipara 9 (18) 11 (22)
Multipara 30 (60) 24 (49)
Previous preterm birth 2 (4) 2 (4)
Candidiasis*
Candida albicans 37 (74) 35 (73)
Moderate or heavy growth 27 (55) 19 (42)
Gravidity = number of pregnancies.
Parity = number of births ≥20 weeks or ≥400 grams.
*Excludes five women (1 clotrimazole and 4 no treatment) for whom growth
information was not reported.
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counter in Australia). And finally, as a vaginally admi-
nistered placebo will necessarily contain an alcohol pre-
servative, it may be biologically active and have an
independent effect on vaginal flora.
Findings from this pilot study support the hypothe-
sized role of Candida in the causal pathway to preterm
birth. First, there was a higher spontaneous preterm
birth rate in women with untreated asymptomatic can-
didiasis compared to those without candidiasis (6.25%
versus 2.99%, RR = 2.2 95%CI 0.5-8.7) consistent with
Candida colonization as a risk factor for preterm birth
[3,15,16]. Second, there was a tendency towards a reduc-
tion in preterm birth for those women treated with clo-
trimazole, consistent with that reported by Kiss [3],
Although the randomized trial design minimises bias by
balancing both known and unknown prognostic factors
in the assignment of treatments [17], the wide confi-
dence intervals around the estimates are also consistent
with a null finding or one of increased risk.
This pilot study established the rate of asymptomatic
vaginal colonization with Candida early in pregnancy
(20%) and at 24-28 weeks (76% untreated and 49% trea-
ted, P < 0.01). Our observed colonization rate of 20% is
consistent with the few published studies. Kiss reported
a 14% colonization rate at 15-19 weeks gestation in
asymptomatic women with singleton pregnancies [3]. A
multicentre prospective US study of an ethnically
diverse population enrolled at 23-26 weeks gestation
reported that 10% of women had moderate-heavy
colonization with Candida a n da m o n gas u b s e tf r o ma
single centre the total Candida colonization rate was
22% (58% light and 42% moderate-heavy colonization)
with 87% C albicans and 94% of women asymptomatic
[4]. Two other single centre US studies reported candi-
diasis rates at 22-30 weeks gestation of 14-38% in
diverse populations of pregnant women [5,18].
The post-treatment colonization rate of 48% in our
pilot study was higher than most, but not all (median
22%, range 0-73%) treatment trials of symptomatic (cul-
ture positive) vaginal candidiasis (thrush) [11]. The latter
trials varied widely in gestational age at enrolment (14-
36 weeks gestation), dose and type of imidazole (1%-2%,
clotrimazole, miconazole & econazole), duration of imi-
dazole therapy (1-14 days) and the duration between
treatment and follow-up [11]. Importantly in the pilot
study, the 10-week average duration between the enrol-
ment and 24-28 week culture was notably longer than
the thrush treatment trials (1-5 weeks) [11]. We cannot
determine whether treatment led to eradication followed
by recolonization or simply a reduction in the level of
Candida growth in individual participants. A larger trial
could determine whether the observed trend to a
reduced level of moderate-heavy Candida colonization
(55% to 42% light colonisation) among treated women
occurred by chance or was a true effect.
We considered carefully the timing of the intervention
and chose to screen for and treat candidiasis in the
early/mid part of the second trimester for a number of
reasons. First, early intervention is consistent with the
Table 3 Trial outcomes for women randomized to clotrimazole and usual care
Trial outcomes Clotrimazole
N=5 0
n (%)
Usual care
N = 49*
n (%)
RR (95% CI)
Preterm birth
Spontaneous/PPROM 1 (2) 3 (6) 0.33 (0.04, 3.03)
Any preterm birth 2 (4) 3 (6) 0.65 (0.11, 3.74)
Pregnancy complications
Gestational diabetes 6 (12) 5 (10) 1.18 (0.38, 3.60)
Antepartum haemorrhage/abruption 2 (4) 4 (8) 0.49 (0.09, 2.55)
Induction of labor
Mode of delivery
16 (32) 11 (22) 1.43 (0.74, 2.75)
Spontaneous vaginal 21 (42) 20 (41) 1.03 (0.64, 1.64)
Instrumental 9 (18) 10 (20) 0.88 (0.39, 1.98)
Caesarean section 20 (40) 18 (37) 1.09 (0.66, 1.80)
Birthweight (grams)
< 2500 2 (4) 2 (4) 0.98 (0.14, 6.68)
2500-3999 42 (84) 42 (86) 0.98 (0.83, 1.16)
≥4000 gms 6 (12) 4 (8) 1.47(0.44, 4.89)
Nursery admission 4 (8) 3 (6) 1.31 (0.31, 5.54)
Relative risk (RR) and 95% confidence interval ((95% CI) of the outcomes in the clotrimazole versus usual care group.
PPROM - preterm prelabor rupture of the membranes.
*One woman who was lost to follow-up is included in the denominator.
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subsequent treatment of candidiasis occurred between
15 weeks and 19 weeks gestation. Second, accumulating
evidence suggests that the role of infection in preterm
birth is a chronic process.
4 Organisms detected in the
uterus before membrane rupture are typically of low
virulence, probably accounting for both the chronicity of
intrauterine infections and the frequent absence of overt
clinical signs of infection.
4 And third, although the trials
of treatment of bacterial vaginosis overall demonstrate
no benefit in the reduction of preterm birth, a positive
treatment effect is seen in those trials that initiated
treatment early in the second trimester [2]. The current
Cochrane Review on bacterial vaginosis concludes that:
“treatment before 20 weeks’ gestation may reduce the
risk of preterm birth. This needs to be further verified
by future trials.” If early pregnancy is the period of vul-
nerability to establishment of inflammatory responses to
low virulence organisms that will increase the risk of
preterm birth, then candidiasis late in pregnancy may be
unimportant.
The safety of any proposed intervention in pregnancy
is of paramount importance. Clotrimazole is classified as
a Category A drug, which has been used by a large
number of pregnant women without any proven
increase in the frequency of malformations or other
direct or indirect harmful effects on the fetus having
been observed [19,20]. Local application of clotrimazole
vaginal pessaries or cream is generally well tolerated
although skin reactions (burning, stinging, or redness)
can occur occasionally. We chose a 6-day treatment
(rather than shorter course) because this is supported by
the Cochrane Systematic Review of treatment for Can-
dida eradication in pregnancy [11] and was the regimen
used in the Kiss trial [3].
Conclusions
We believe a large, adequately powered, randomized
trial of clotrimazole to prevent preterm birth in women
with asymptomatic candidiasis is both feasible and war-
ranted. This pilot study has informed the development
and funding application for such a trial [21]. Should this
intervention prove effective, a screening protocol could
be readily incorporated into routine antenatal care and
treatment is available and widely accepted. If it can be
demonstrated that treatment of asymptomatic candidia-
sis reduces preterm births this will change current prac-
tice internationally and will directly impact the
management of every pregnant woman.
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